Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market

Table Of Content

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market, By Type
1. Introduction
  1. Market Size and Forecast, By Type
2. Active Pharmaceutical Ingredient (API) Manufacturing
  1. Market Size and Forecast, By Region
3. Finished Dosage Formulation (FDF) Development and Manufacturing
  1. Market Size and Forecast, By Region
4. Secondary Packaging
  1. Market Size and Forecast, By Region
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market, By Application
1. Introduction
  1. Market Size and Forecast, By Application
2. Big Pharmaceutical Companies
  1. Market Size and Forecast, By Region
3. Small and Med-Size Pharmaceutical Companies
  1. Market Size and Forecast, By Region
4. Generic Pharmaceutical Companies
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  2. U.S.
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  2. U.K.
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  2. China
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  3. Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  2. UAE
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  2. Brazil
    1. By Type
      1. Active Pharmaceutical Ingredient (API) Manufacturing
      2. Finished Dosage Formulation (FDF) Development and Manufacturing
      3. Secondary Packaging
    2. By Application
      1. Big Pharmaceutical Companies
      2. Small and Med-Size Pharmaceutical Companies
      3. Generic Pharmaceutical Companies
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2024
1. Introduction
2. Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Share Analysis, 2024 (%)
  1. Market Share Analysis, 2024
  2. Competition Ranking, 2024
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Catalent Inc.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Recipharm AB
3. Jubilant Life Sciences Ltd
4. Patheon Inc.
5. Boehringer Ingelheim Group
6. Pfizer CentreSource
7. Aenova Holding GmbH
8. Famar SA
9. Baxter Biopharma Solutions
10. Lonza Group
11. CMIC Holdings Co. Ltd
12. Covance Inc.
13. Syneos Health Inc.
14. LSK Global Pharma Service Co. Ltd
15. Novotech Pty Ltd
16. PAREXEL International Corporation
17. Pharmaceutical Product Development LLC
18. PRA Health Sciences Inc.
19. Quanticate Ltd
20. IQVIA Holdings Inc.
21. SGS Life Science Services SA
22. Hangzhou Tigermed Consulting Co. Ltd
23. Samsung Bioepis Co. Ltd
24. WuXi AppTec Inc.
25. Sagimet Biosciences (3V Biosciences Inc.)

	


A PHP Error was encountered

Severity: Warning
Message:  Undefined array key "list_tbl_fig"
Filename: reports/toc.php
Line Number: 79


	Backtrace:
	
		
	
		
	
		
			
			File: /var/www/html/application/views/frontend/reports/toc.php

			Line: 79

			Function: _error_handler			

		
	
		
	
		
	
		
			
			File: /var/www/html/application/controllers/Web.php

			Line: 215

			Function: view			

		
	
		
	
		
			
			File: /var/www/html/index.php

			Line: 316

			Function: require_once

Check Discount

Get Free Sample

Buy Now

Key Topics Covered

Market Factors (Including Drivers and Restraint)
Market Trends
Market Estimates and Forcasts
Competitive Analysis
Future Market Opportunities

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size, Share and Growth Analysis Report By Type, By Application and By Region (North America (U.S., Canada) Europe (U.K. . . . .

Table Of Content

A PHP Error was encountered